Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2005

01-09-2005 | Original Article

Hyperhomocysteinemia in patients with Behçet’s disease: is it due to inflammation or therapy?

Authors: Zeki Yesilova, Salih Pay, Cagatay Oktenli, Ugur Musabak, Kenan Saglam, S. Yavuz Sanisoglu, Kemal Dagalp, M. Kemal Erbil, Ismail H. Kocar

Published in: Rheumatology International | Issue 6/2005

Login to get access

Abstract

Considerable discrepancies exist in the literature with respect to plasma total homocysteine (tHcy) levels in Behçet’s disease (BD). The aim of this study was to evaluate tHcy concentrations in these patients. Thirty-two patients with BD and 20 age- and body mass index-matched healthy volunteers were enrolled. Plasma tHcy concentrations were significantly higher, while vitamin B12 and folate levels were significantly lower in patients with thrombosis and eye involvement than those without. C-reactive protein levels also correlated significantly in a negative manner with vitamin B12 and folate but positively with tHcy. In conclusion, increased use or accelerated catabolism of folate and vitamin B12 due to chronic inflammation and moderately increased tHcy concentrations related with deficiency of these cofactors, and immunosuppressive drug administration might be potential threats of vascular disease in BD.
Literature
1.
Behçet H (1937) Ueber rezidivierende Aphtoese, durch ein Virus verursachte Geschwuere am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr 105:1152
2.
Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R (1996) Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet’s disease. Ann Rheum Dis 55:128–133PubMed
3.
O’Duffy JD (1990) Vasculitis in Behçet’s disease. Rheum Dis Clin North Am 16:423–431PubMed
4.
Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S (1992) Vascular involvement in Behçet’s disease. J Rheumatol 19:402–410PubMed
5.
Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T (1996) Coagulation factor V mutation increases the risk of venous thrombosis in Behçet’s disease. Br J Rheumatol 35:1178–1180PubMed
6.
Kuzu MA, Ozaslan C, Koksoy C, Gurler A, Tuzuner A (1994) Vascular involvement in Behçet’s disease: 8-year audit. World J Surg 18:948–954PubMed
7.
Yazici H, Hekim N, Ozbakir F, Yurdakul S, Tuzun Y, Pazarli H, Muftuoglu A (1987) Von Willebrand factor in Behçet’s disease. J Rheumatol 14:305–306PubMed
8.
Lee YJ, Kang SW, Yang JI, Choi Y, Sheen D, Lee EB, Choi S, Song YW (2002) Coagulation parameters and plasma total homocysteine levels in Behçet’s disease. Thromb Res 106:19–24CrossRefPubMed
9.
McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111–128PubMed
10.
Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg I (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693–2698PubMed
11.
Harker LA, Ross R, Slichter SJ, Scott CR (1976) Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58:731–741PubMed
12.
Hajjar KA (1993) Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91:2873–2879PubMed
13.
Majors A, Ehrhart LA, Pezacka EH (1997) Homocysteine as a risk factor vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 17:2074–2081PubMed
14.
Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, Loscalzo J (1997) Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272:17012–17017CrossRefPubMed
15.
Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042–1050PubMed
16.
Harker LA, Slichter SJ, Scott CR, Ross R (1974) Homocysteinemia. Vascular injury and arterial thrombosis. N Engl J Med 291:537–543
17.
Ratnoff OD (1968) Activation of Hageman factor by L-homocysteine. Science 162:1007–1009
18.
Rodgers GM, Kane WH (1986) Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 77:1909–1916PubMed
19.
Lentz SR, Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906–1914PubMed
20.
Nishinaga M, Ozawa T, Shimada K (1993) Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92:1381–1386PubMed
21.
Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, Haber E, Chang TH, Schlegel R, Lee ME (1996) Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 97:146–153PubMed
22.
Loscalzo J (1996) The oxidant stress of hyperhomocysteinemia. J Clin Invest 98:5–7PubMed
23.
Frauscher G, Karnaukhova E, Muehl A, Hoeger H, Lubec B (1995) Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid—additional mechanisms in homocysteine induced endothelial damage? Life Sci 57:813–817CrossRefPubMed
24.
International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080PubMed
25.
Araki A & Sako Y (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromat 422: 43–52PubMed
26.
Zar JH (1996) Biostatistical Analysis. Prentice Hall
27.
Armitage B, Berry G, Matthews JNS (2002) Statistical methods in medical research. Blackwell Science, London
28.
Nalbant S, Aktay D, Cingozbay Y, Top C, Kucukardali Y, Avsar K, Danaci M (2003) Homocysteine and Behçet disease. J Clin Rheumatol 9:65–66CrossRef
29.
Aksu K, Turgan N, Oksel F, Keser G, Ozmen D, Kitapcioglu G, Gumusdis G, Bayindir O, Doganavsargil E (2001) Hyperhomocysteinemia in Behçet’s disease. Rheumatology 40:687–690CrossRefPubMed
30.
Korkmaz C, Bozan B, Kosar M, Sahin F, Gulbas Z (2002) Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet’s syndrome? Clin Exp Rheumatol 20:30–34
31.
Er H, Evereklioglu C, Cumurcu T, Turkoz Y, Ozerol E, Sahin K, Doganay S (2002) Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet’s disease. Br J Ophthalmol 86:653–657CrossRefPubMed
32.
Bekpinar S, Kocak H, Unlucerci Y, Genc S, Akdag KA, Gogus F (2003) The evaluation of C-reactive protein, homocysteine and vitamin B6 concentrations in Behçet and rheumatoid arthritis disease. Clin Chim Acta 329:143–145CrossRefPubMed
33.
Okka M, Ozturk M, Kockar MC, Bavbek N, Rasier Y, Gunduz K, Korkar MC (2002) Plasma homocysteine level and uveitis in Behçet’s disease. Isr Med Assoc J 4:931–934PubMed
34.
Fresko I, Hamuryudan V, Demir M, Hizli N, Sayman H, Melikoglu M, Tunc R, Yurdakul S, Yazici H (2001) Intestinal permeability in Behçet’s syndrome. Ann Rheum Dis 60:65–66CrossRefPubMed
35.
Muftuoglu AU, Yazici H, Yurdakul S, Tuzun Y, Pazarli H, Gungen G, Deniz S (1986) Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 25:235–239PubMed
36.
Folsom AR, Desvarieux M, Nieto FJ, Boland LL, Ballantyne CM, Chambless LE (2003) B vitamin status and inflammatory markers. Atherosclerosis 169:169–174CrossRefPubMed
37.
de Jong SC, Stehouwer CD, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ (1997) Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 78:1332–1337
38.
Yxfeldt A, Wallberg-Jonsson S, Hultdin J, Rantapaa-Dahlqvist S (2003) Homocysteine in a patient with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol 32:205–210PubMed
39.
Chiang EP, Bagley PJ, Selhub J, Nadeau M, Roubenoff R (2003) Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 114:283–287CrossRefPubMed
40.
Kuller LH, Evans RW (1998) Homocysteine, vitamins, and cardiovascular disease. Circulation 98:196–199PubMed
41.
Pronai L, Ichikawa Y, Nakazawa H, Arimory S (1991) Enhanced superoxide generation and the decreased superoxide scavenging activity of peripheral blood leukocytes in Behçet’s disease: effects of colchicine. Clin Exp Rheum 9:227–233PubMed
42.
Orem A, Efe H, Deger O, Cimsit G, Uydu HA, Vanizor B (1997) Relationship between lipid peroxidation and disease activity in patients with Behçet’s disease. J Dermatol Sci 16:11–16CrossRefPubMed
43.
Kose K, Yazici C, Ascioglu O (2001) The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behçet’s disease. Clin Biochem 34:125–129CrossRefPubMed
44.
Bayes B, Pastor MC, Bonal J, Junca J, Romero R (2001) Homocysteine and lipid peroxidation in hemodialysis: role of folic acid and vitamin E. Nephrol Dial Transplant 16:2172–2175CrossRefPubMed
45.
Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, Feingold KR, Grunfeld C (2000) Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 20:1536–1542PubMed
46.
Niwa Y, Miyake S, Sakane T, Shingen M, Yokoyama M (1982) Auto-oxidative damage in Behçet’s disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 49:247–255PubMed
47.
Holven K, Aukrust P, Holm T, Ose L, Nenseter M (2002) Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 22:699–703CrossRefPubMed
48.
Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H (1996) Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 61: 509–512PubMed
49.
Cole DEC, Ross HJ, Evrovski J, Langman LJ, Miner SES, Daly PA, Wong PY (1998) Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem 44:2307–2312PubMed
50.
Arnadottir M, Hultberg B, Wahlberg J, Fellström B, Dimeny E (1998) Serum total homocysteine concentration before and after renal transplantation. Kidney Int 54: 1380–1384CrossRefPubMed
51.
Ducloux D, Fournier V, Rebibou JM, Bresson-Vautrin C, Gibey R, Chalopin JM (1998) Hyperhomocysteinemia in renal transplant recipients with and without cyclosporine. Clin Nephrol 49:232–235PubMed
52.
Ducloux D, Ruedin C, Gibey R, Chalopin JM (1998) Prevalence, determinants, and clinical significance of hyperhomocysteinemia in renal-transplant recipients. Nephrol Dial Transplant 13:2890
53.
Woodside JV, Fogarty DG, Lightbody JH, Loughrey CM, Yarnell JW, Maxwell AP, Young IS (1999) Homocysteine and B- group vitamins in renal transplant patients. Clin Chim Acta 282:157–166PubMed
54.
Gupta A, Moustapha A, Jacobsen DW, Goormastic M, Tuzcu EM, Hobbs R, Young J, James K, McCarthy P, van Lente F, Green R, Robinson K (1998) High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 65:544–550PubMed
55.
Fogarty DG, Woodside J, Lightbody JM, Maxwell AP (1996) Plasma homocysteine in renal transplant recipients. J Am Soc Nephrol 7:1931
56.
Fernandez-Miranda C, Gomez P, Diaz-Rubio P, Estenoz J, Carrillo JL, Andres A, Morales JM (2000) Plasma homocystenie levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplant 14:110–114PubMed
57.
Kim SI, Yoo TH, Song HY, Hwang JH, Lee HY, Han DS, Moon JI, Kim YS, Park KI, Paenk KJ, Choi KH. (2000) Hyperhomocysteinemia in renal transplant recipients with cyclosporine. Transplant Proceed 32:1878–1879CrossRef
58.
Stein G, Muller A, Busch M, Fleck C, Sperschneider H (2001) Homocysteine, its metabolites, and B-group vitamins in renal transplant patients. Kidney Int 78: S262-S265
59.
Mehra MR, Uber PA, Scott RL, Park MH, Milani RV (2002) Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: homocysteine, C-reactive protein, and mean platelet volume. Transplant Proceed 34:1866–1868CrossRef
60.
Ignatescu M, Fodinger M, Kletzmayr J, Bieglmayer C, Horl W, Sunder-Plassmann G (2001) Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells? Kidney Int 59: S258-S261
61.
Hultberg B, Arnadottir M (2003) The effect of cyclosporine on homocysteine export in human cell lines. Transplant Proceed 35:801–802CrossRef
62.
Fodinger M, Wolfl G, Fischer G, Rasoul-Rockenschaub S, Schmid R, Horl WH, Sunder-Plassmann G (1999) Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. Kidney Int 55: 1072–1080PubMed
63.
Bostom AG, Gohh RY, Tsai MY, Hopkins-Garcia BJ, Nadeau MR, Bianchi LA, Jacques PF, Rosenberg IH, Selhub J (1997) Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal recipients. Arterioscler Thromb Vasc Biol 17:1894–1900PubMed
64.
Kim MH, Kim E, Passen EL, Meyer J, Kang SS (1997) Cortisol and estradiol: nongenetic factors for hyperhomocysteinemia. Metabolism 46:247–249PubMed
65.
Lazzerini PE, Capecchi PL, Bisogno S, Galeazzi M, Marcolonga R, Laghi Pasini F (2003) Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment. Ann Rheum Dis 62:694–695CrossRefPubMed
Metadata
Title
Hyperhomocysteinemia in patients with Behçet’s disease: is it due to inflammation or therapy?
Authors
Zeki Yesilova
Salih Pay
Cagatay Oktenli
Ugur Musabak
Kenan Saglam
S. Yavuz Sanisoglu
Kemal Dagalp
M. Kemal Erbil
Ismail H. Kocar
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-004-0466-9

Other articles of this Issue 6/2005

Rheumatology International 6/2005 Go to the issue

Original Article

Multivariate analysis of biochemical markers in synovial fluid from the shoulder joint for diagnosis of rotator cuff tears

Letter to the Editor

Serum RANTES, MIP-1α, and MCP-1 levels in Behçet’s disease

Letter to the Editor

Selective immunoglobulin A deficiency and primary antiphospholipid syndrome

Original Article

Arthritis or vasculitis as presenting symptoms of Crohn’s disease

Short Communication

The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study

Original Article

Radiographic hip osteoarthritis and acetabular dysplasia in Turkish men and women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits